Vitality Watch

Dossier pubmed preclinical 25-jul-2026
Animal model, organoid, or cell-culture result — not yet human

SIRT3 inhibition promotes age-associated vascular impairment by mediating mitochondrial dysfunction and endothelial-to-mesenchymal transition.

Key claim: SIRT3 deficiency promotes age-related vascular impairment by driving mitochondrial dysfunction and endothelial-to-mesenchymal transition, nominating SIRT3 as a potential target to delay vascular aging.

Abstract

BACKGROUND: Vascular aging profoundly impacts on cardiovascular disease. Sirtuin 3 (SIRT3) is a key regulator of metabolic homeostasis whose expression declines with age; however, the mechanisms linking SIRT3 deficiency to age-associated vascular impairment remain unclear. Here, we investigated whether SIRT3 deficiency drives age-associated vascular impairment by inducing mitochondrial dysfunction and initiating endothelial-to-mesenchymal transition (EndMT). METHODS: Vascular morphology, aging-related protein expression, and endothelium-dependent vasorelaxation were evaluated in young (5-month-old) and aged (21-month-old) wild-type mice, alongside Sirt3 knockout (KO) mice. EndMT was assessed using immunofluorescence and immunoblotting. Mitochondrial function was examined by assessing mitochondrial morphology, determining the protein expression of mitochondrial biogenesis-related factors and superoxide dismutase 2, and measuring mitochondrial reactive oxygen species levels. In vitro, human umbilical vein endothelial cells (HUVECs) were transfected with SIRT3-targeting siRNA and treated with HOto induce premature senescence, after which mitochondrial function and EndMT marker levels were analyzed. RESULTS: Vascular aging was characterized by increased expression of aging-related proteins, endothelial dysfunction, and medial calcification and fibrosis, which were linked to EndMT and mitochondrial dysfunction in aged endothelial cells (ECs). SIRT3 expression was downregulated in aging vascular ECs. Sirt3 KO mice exhibited exacerbated vascular calcification and fibrosis, associated with the promotion of aging-induced EndMT and the aggravation of mitochondrial dysfunction. Silencing SIRT3 in prematurely senescent HUVECs confirmed its role in driving EndMT and mitochondrial dysfunction. CONCLUSIONS: SIRT3 deficiency promotes age-related vascular impairment potentially by mediating EndMT and mitochondrial dysfunction, Thus, SIRT3 represents a potential therapeutic target for delaying vascular aging and associated cardiovascular diseases.

Why this matters

SIRT3 extends the sirtuin/vascular-aging story from SIRT1-centric VSMC narratives into a mitochondrial-sirtuin arm acting on endothelial cells, with endothelial-to-mesenchymal transition as the proximate phenotype. The finding reinforces an EndMT convergence point already touched by the FABP3/NF-κB axis and situates mitochondrial redox control as a shared upstream node where sirtuin biology, mitochondrial dysfunction, and endothelial senescence intersect. Evidence remains at the aged-mouse, Sirt3-KO, and HUVEC level — no human readout and no SIRT3-activator intervention tested here.

Source

Link

Briefing card

SIRT3 inhibition promotes age-associated vascular impairment by mediating mitochondrial dysfunction and endothelial-to-mesenchymal transition.
Stage: preclinical · pubmed · 25-jul-2026

Applies to preclinical SIRT3 and endothelial-aging research — no human-actionable consequence from this mouse/cell study.

SIRT3 deficiency promotes age-related vascular impairment by driving mitochondrial dysfunction and endothelial-to-mesenchymal transition, nominating SIRT3 as a potential target to delay vascular aging.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.exger.2026.113250

build build 880 · 2bcef25 · 2026-11-18